Peter Clark
Last active: 2/12/2015

Profile

None provided

Publications

The following timeline graph is generated from all co-authored publications.

Featured publications are shown below:

  1. Statin use is associated with improved survival in patients undergoing surgery for renal cell carcinoma. Kaffenberger SD, Lin-Tsai O, Stratton KL, Morgan TM, Barocas DA, Chang SS, Cookson MS, Herrell SD, Smith JA, Clark PE (2015) Urol Oncol 33(1): 21.e11-21.e17
    › Primary publication · 25456998 (PubMed) · PMC4274038 (PubMed Central)
  2. Renal cell cancer histological subtype distribution differs by race and sex. Lipworth L, Morgans AK, Edwards TL, Barocas DA, Chang SS, Herrell SD, Penson DF, Resnick MJ, Smith JA, Clark PE (2016) BJU Int 117(2): 260-5
    › Primary publication · 25307281 (PubMed)
  3. Lack of P16ink4a over expression in penile squamous cell carcinoma is associated with recurrence after lymph node dissection. Tang DH, Clark PE, Giannico G, Hameed O, Chang SS, Gellert LL (2015) J Urol 193(2): 519-25
    › Primary publication · 25261804 (PubMed)
  4. Hypoalbuminaemia is associated with mortality in patients undergoing cytoreductive nephrectomy. Corcoran AT, Kaffenberger SD, Clark PE, Walton J, Handorf E, Piotrowski Z, Tomaszewski JJ, Ginzburg S, Mehrazin R, Plimack E, Chen DY, Smaldone MC, Uzzo RG, Morgan TM, Kutikov A (2015) BJU Int 116(3): 351-7
    › Primary publication · 25123843 (PubMed)
  5. Impact of complications and hospital-free days on health related quality of life 1 year after radical cystectomy. Ritch CR, Cookson MS, Chang SS, Clark PE, Resnick MJ, Penson DF, Smith JA, May AT, Anderson CB, You C, Lee H, Barocas DA (2014) J Urol 192(5): 1360-4
    › Primary publication · 24928268 (PubMed)
  6. Progress made in the use of animal models for the study of high-risk, nonmuscle invasive bladder cancer. Lin-Tsai O, Taylor JA, Clark PE, Adam RM, Wu XR, DeGraff DJ (2014) Curr Opin Urol 24(5): 512-6
    › Primary publication · 24921908 (PubMed)
  7. Biochemical recurrence-free survival after robotic-assisted laparoscopic vs open radical prostatectomy for intermediate- and high-risk prostate cancer. Ritch CR, You C, May AT, Herrell SD, Clark PE, Penson DF, Chang SS, Cookson MS, Smith JA, Barocas DA (2014) Urology 83(6): 1309-15
    › Primary publication · 24746665 (PubMed)
  8. NF-κB gene signature predicts prostate cancer progression. Jin R, Yi Y, Yull FE, Blackwell TS, Clark PE, Koyama T, Smith JA, Matusik RJ (2014) Cancer Res 74(10): 2763-72
    › Primary publication · 24686169 (PubMed) · PMC4024337 (PubMed Central)
  9. F2-isoprostanes as a biomarker of oxidative stress in the mouse bladder. Clayton DB, Stephany HA, Ching CB, Rahman SA, Tanaka ST, Thomas JC, Pope JC, Adams MC, Brock JW, Clark PE, Hayward SW, Matusik RJ, Milne GL (2014) J Urol 191(5 Suppl): 1597-601
    › Primary publication · 24679873 (PubMed)
  10. Developments and controversies in the management of noninvasive bladder cancer. Bassett JC, Eifler JB, Resnick MJ, Clark PE (2014) Curr Opin Oncol 26(3): 299-304
    › Primary publication · 24638080 (PubMed)
  11. Surgical intervention for symptomatic benign prostatic hyperplasia is correlated with expression of the AP-1 transcription factor network. Lin-Tsai O, Clark PE, Miller NL, Fowke JH, Hameed O, Hayward SW, Strand DW (2014) Prostate 74(6): 669-79
    › Primary publication · 24500928 (PubMed) · PMC4160824 (PubMed Central)
  12. T1 high-grade bladder cancer recurring after BCG therapy: radical cystectomy is still the best approach. Pro. Clark PE (2013) Oncology (Williston Park) 27(9): 872, 921
    › Primary publication · 24282982 (PubMed)
  13. Blood loss associated with radical cystectomy: a prospective, randomized study comparing Impact LigaSure vs. stapling device. Thompson IM, Kappa SF, Morgan TM, Barocas DA, Bischoff CJ, Keegan KA, Stratton KL, Clark PE, Resnick MJ, Smith JA, Cookson MS, Chang SS (2014) Urol Oncol 32(1): 45.e11-5
    › Primary publication · 24054870 (PubMed) · PMC4469381 (PubMed Central)
  14. Incidence and predictors of understaging in patients with clinical T1 urothelial carcinoma undergoing radical cystectomy. Ark JT, Keegan KA, Barocas DA, Morgan TM, Resnick MJ, You C, Cookson MS, Penson DF, Davis R, Clark PE, Smith JA, Chang SS (2014) BJU Int 113(6): 894-9
    › Primary publication · 24053444 (PubMed) · PMC3874077 (PubMed Central)
  15. Current concepts in penile cancer. Spiess PE, Horenblas S, Pagliaro LC, Biagioli MC, Crook J, Clark PE, Greenberg RE, Ercole CE (2013) J Natl Compr Canc Netw 11(5): 617-24
    › Primary publication · 23667210 (PubMed)
  16. Penile cancer: Clinical Practice Guidelines in Oncology. Clark PE, Spiess PE, Agarwal N, Biagioli MC, Eisenberger MA, Greenberg RE, Herr HW, Inman BA, Kuban DA, Kuzel TM, Lele SM, Michalski J, Pagliaro L, Pal SK, Patterson A, Plimack ER, Pohar KS, Porter MP, Richie JP, Sexton WJ, Shipley WU, Small EJ, Trump DL, Wile G, Wilson TG, Dwyer M, Ho M, National Comprehensive Cancer Network (2013) J Natl Compr Canc Netw 11(5): 594-615
    › Primary publication · 23667209 (PubMed) · PMC4042432 (PubMed Central)
  17. Bladder cancer. Clark PE, Agarwal N, Biagioli MC, Eisenberger MA, Greenberg RE, Herr HW, Inman BA, Kuban DA, Kuzel TM, Lele SM, Michalski J, Pagliaro LC, Pal SK, Patterson A, Plimack ER, Pohar KS, Porter MP, Richie JP, Sexton WJ, Shipley WU, Small EJ, Spiess PE, Trump DL, Wile G, Wilson TG, Dwyer M, Ho M, National Comprehensive Cancer Network (NCCN) (2013) J Natl Compr Canc Netw 11(4): 446-75
    › Primary publication · 23584347 (PubMed)
  18. Restaging transurethral resection for non-muscle invasive bladder cancer: who, why, when, and how? Ritch CR, Clark PE, Morgan TM (2013) Urol Clin North Am 40(2): 295-304
    › Primary publication · 23540786 (PubMed)
  19. Management of superficial and muscle-invasive urothelial cancers of the bladder. Resnick MJ, Bassett JC, Clark PE (2013) Curr Opin Oncol 25(3): 281-8
    › Primary publication · 23425709 (PubMed)
  20. Anatomic basis for lymph node counts as measure of lymph node dissection extent: a cadaveric study. Davies JD, Simons CM, Ruhotina N, Barocas DA, Clark PE, Morgan TM (2013) Urology 81(2): 358-63
    › Primary publication · 23374802 (PubMed)
  21. Ureteroenteric anastomotic strictures after radical cystectomy-does operative approach matter? Anderson CB, Morgan TM, Kappa S, Moore D, Clark PE, Davis R, Penson DF, Barocas DA, Smith JA, Cookson MS, Chang SS (2013) J Urol 189(2): 541-7
    › Primary publication · 23260561 (PubMed)
  22. ICUD-EAU International Consultation on Bladder Cancer 2012: Screening, diagnosis, and molecular markers. Kamat AM, Hegarty PK, Gee JR, Clark PE, Svatek RS, Hegarty N, Shariat SF, Xylinas E, Schmitz-Dräger BJ, Lotan Y, Jenkins LC, Droller M, van Rhijn BW, Karakiewicz PI, International Consultation on Urologic Disease-European Association of Urology Consultation on Bladder Cancer 2012 (2013) Eur Urol 63(1): 4-15
    › Primary publication · 23083902 (PubMed)
  23. Volume outcomes of cystectomy--is it the surgeon or the setting? Morgan TM, Barocas DA, Keegan KA, Cookson MS, Chang SS, Ni S, Clark PE, Smith JA, Penson DF (2012) J Urol 188(6): 2139-44
    › Primary publication · 23083864 (PubMed)
  24. Imaging the clear cell renal cell carcinoma proteome. Morgan TM, Seeley EH, Fadare O, Caprioli RM, Clark PE (2013) J Urol 189(3): 1097-103
    › Primary publication · 23009866 (PubMed) · PMC3570618 (PubMed Central)
  25. Salvage robotic assisted laparoscopic radical prostatectomy: a single institution, 5-year experience. Kaffenberger SD, Keegan KA, Bansal NK, Morgan TM, Tang DH, Barocas DA, Penson DF, Davis R, Clark PE, Chang SS, Cookson MS, Herrell SD, Smith JA (2013) J Urol 189(2): 507-13
    › Primary publication · 23000849 (PubMed) · PMC3698478 (PubMed Central)
  26. ABO blood group is a predictor of survival in patients undergoing surgery for renal cell carcinoma. Kaffenberger SD, Morgan TM, Stratton KL, Boachie AM, Barocas DA, Chang SS, Cookson MS, Herrell SD, Smith JA, Clark PE (2012) BJU Int 110(11 Pt B): E641-6
    › Primary publication · 22958439 (PubMed)
  27. Lymph node yield at radical cystectomy predicts mortality in node-negative and not node-positive patients. Morgan TM, Barocas DA, Penson DF, Chang SS, Ni S, Clark PE, Smith JA, Cookson MS (2012) Urology 80(3): 632-40
    › Primary publication · 22795379 (PubMed)
  28. Association between physical activity, lower urinary tract symptoms (LUTS) and prostate volume. Fowke JH, Phillips S, Koyama T, Byerly S, Concepcion R, Motley SS, Clark PE (2013) BJU Int 111(1): 122-8
    › Primary publication · 22726636 (PubMed) · PMC3460041 (PubMed Central)
  29. Voiding function in women with orthotopic neobladder urinary diversion. Anderson CB, Cookson MS, Chang SS, Clark PE, Smith JA, Kaufman MR (2012) J Urol 188(1): 200-4
    › Primary publication · 22591966 (PubMed)
  30. Loss of the urothelial differentiation marker FOXA1 is associated with high grade, late stage bladder cancer and increased tumor proliferation. DeGraff DJ, Clark PE, Cates JM, Yamashita H, Robinson VL, Yu X, Smolkin ME, Chang SS, Cookson MS, Herrick MK, Shariat SF, Steinberg GD, Frierson HF, Wu XR, Theodorescu D, Matusik RJ (2012) PLoS One 7(5): e36669
    › Primary publication · 22590586 (PubMed) · PMC3349679 (PubMed Central)
  31. Recovery of urinary function after radical prostatectomy: identification of trajectory cluster groups. Anderson CB, Kaufman MR, Dietrich MS, Barocas DA, Chang SS, Cookson MS, Smith JA, Clark PE, Herrell SD (2012) J Urol 187(4): 1346-51
    › Primary publication · 22341278 (PubMed)
  32. Multimodal therapies for muscle-invasive urothelial carcinoma of the bladder. Keegan KA, Resnick MJ, Clark PE (2012) Curr Opin Oncol 24(3): 278-83
    › Primary publication · 22273550 (PubMed) · PMC3698482 (PubMed Central)
  33. National trends in the use of partial nephrectomy: a rising tide that has not lifted all boats. Patel SG, Penson DF, Pabla B, Clark PE, Cookson MS, Chang SS, Herrell SD, Smith JA, Barocas DA (2012) J Urol 187(3): 816-21
    › Primary publication · 22248514 (PubMed)
  34. Comprehensive handbook for developing a bladder cancer cystectomy database. Lotan Y, Amiel G, Boorjian SA, Clark PE, Droller M, Gingrich JR, Guzzo TJ, Inman BA, Kamat AM, Karsh L, Nielsen ME, Smith ND, Shariat SF, Svatek RS, Taylor JM, Bladder Cancer Think Tank, Bladder Cancer Advocacy Network (2013) Urol Oncol 31(6): 812-26
    › Primary publication · 22056403 (PubMed)
  35. Prostate size as a predictor of Gleason score upgrading in patients with low risk prostate cancer. Davies JD, Aghazadeh MA, Phillips S, Salem S, Chang SS, Clark PE, Cookson MS, Davis R, Herrell SD, Penson DF, Smith JA, Barocas DA (2011) J Urol 186(6): 2221-7
    › Primary publication · 22014803 (PubMed)
  36. β-Catenin and K-RAS synergize to form primitive renal epithelial tumors with features of epithelial Wilms' tumors. Clark PE, Polosukhina D, Love H, Correa H, Coffin C, Perlman EJ, de Caestecker M, Moses HL, Zent R (2011) Am J Pathol 179(6): 3045-55
    › Primary publication · 21983638 (PubMed) · PMC3260797 (PubMed Central)
  37. Tumour size, tumour complexity, and surgical approach are associated with nephrectomy type in small renal cortical tumours treated electively. Broughton GJ, Clark PE, Barocas DA, Cookson MS, Smith JA, Herrell SD, Chang SS (2012) BJU Int 109(11): 1607-13
    › Primary publication · 21939493 (PubMed)
  38. When urothelial differentiation pathways go wrong: implications for bladder cancer development and progression. DeGraff DJ, Cates JM, Mauney JR, Clark PE, Matusik RJ, Adam RM (2013) Urol Oncol 31(6): 802-11
    › Primary publication · 21924649 (PubMed) · PMC4886548 (PubMed Central)
  39. The relationship between perioperative blood transfusion and overall mortality in patients undergoing radical cystectomy for bladder cancer. Morgan TM, Barocas DA, Chang SS, Phillips SE, Salem S, Clark PE, Penson DF, Smith JA, Cookson MS (2013) Urol Oncol 31(6): 871-7
    › Primary publication · 21906965 (PubMed) · PMC3253245 (PubMed Central)
  40. Serum methionine metabolites are risk factors for metastatic prostate cancer progression. Stabler S, Koyama T, Zhao Z, Martinez-Ferrer M, Allen RH, Luka Z, Loukachevitch LV, Clark PE, Wagner C, Bhowmick NA (2011) PLoS One 6(8): e22486
    › Primary publication · 21853037 (PubMed) · PMC3154200 (PubMed Central)
  41. Assessing the surgical skills of urology residents after preurology general surgery training: the surgical skills learning needs of new urology residents. Mitchell RE, Clark PE, Scarpero HM (2011) J Surg Educ 68(5): 341-6
    › Primary publication · 21821209 (PubMed)
  42. Predicting the probability of 90-day survival of elderly patients with bladder cancer treated with radical cystectomy. Morgan TM, Keegan KA, Barocas DA, Ruhotina N, Phillips SE, Chang SS, Penson DF, Clark PE, Smith JA, Cookson MS (2011) J Urol 186(3): 829-34
    › Primary publication · 21788035 (PubMed) · PMC6472701 (PubMed Central)
  43. PPARγ: a molecular link between systemic metabolic disease and benign prostate hyperplasia. Jiang M, Strand DW, Franco OE, Clark PE, Hayward SW (2011) Differentiation 82(4-5): 220-36
    › Primary publication · 21645960 (PubMed) · PMC3174339 (PubMed Central)
  44. Urinary collecting system invasion is a predictor for overall and disease-specific survival in locally invasive renal cell carcinoma. Anderson CB, Clark PE, Morgan TM, Stratton KL, Herrell SD, Davis R, Cookson MS, Smith JA, Chang SS (2011) Urology 78(1): 99-104
    › Primary publication · 21550647 (PubMed)
  45. Bladder cancer. Morgan TM, Keegan KA, Clark PE (2011) Curr Opin Oncol 23(3): 275-82
    › Primary publication · 21311329 (PubMed)
  46. Preoperative nutritional status is an important predictor of survival in patients undergoing surgery for renal cell carcinoma. Morgan TM, Tang D, Stratton KL, Barocas DA, Anderson CB, Gregg JR, Chang SS, Cookson MS, Herrell SD, Smith JA, Clark PE (2011) Eur Urol 59(6): 923-8
    › Primary publication · 21295907 (PubMed) · PMC3085569 (PubMed Central)
  47. Detection of tumor cells in the bone offers independent prognostic value in bladder cancer patients: the clinical and basic science perspective. DeGraff DJ, Clark PE (2011) Eur Urol 60(2): 239-40
    › Primary publication · 21195537 (PubMed)
  48. Tumor volume as a predictor of adverse pathologic features and biochemical recurrence (BCR) in radical prostatectomy specimens: a tale of two methods. Thompson IM, Salem S, Chang SS, Clark PE, Davis R, Herrell SD, Kordan Y, Baumgartner R, Phillips S, Smith JA, Cookson MS, Barocas DA (2011) World J Urol 29(1): 15-20
    › Primary publication · 21079968 (PubMed)
  49. Effect of preoperative nutritional deficiency on mortality after radical cystectomy for bladder cancer. Gregg JR, Cookson MS, Phillips S, Salem S, Chang SS, Clark PE, Davis R, Stimson CJ, Aghazadeh M, Smith JA, Barocas DA (2011) J Urol 185(1): 90-6
    › Primary publication · 21074802 (PubMed) · PMC3049248 (PubMed Central)
  50. Determining factors for hospital discharge status after radical cystectomy in a large contemporary cohort. Aghazadeh MA, Barocas DA, Salem S, Clark PE, Cookson MS, Davis R, Gregg J, Stimson CJ, Smith JA, Chang SS (2011) J Urol 185(1): 85-9
    › Primary publication · 21074199 (PubMed)
  51. A simple, effective method to create laparoscopic renal protective hypothermia with cold saline surface irrigation: clinical application and assessment. Kijvikai K, Viprakasit DP, Milhoua P, Clark PE, Herrell SD (2010) J Urol 184(5): 1861-6
    › Primary publication · 20846690 (PubMed)
  52. Early and late perioperative outcomes following radical cystectomy: 90-day readmissions, morbidity and mortality in a contemporary series. Stimson CJ, Chang SS, Barocas DA, Humphrey JE, Patel SG, Clark PE, Smith JA, Cookson MS (2010) J Urol 184(4): 1296-300
    › Primary publication · 20723939 (PubMed)
  53. Comparative analysis of whole mount processing and systematic sampling of radical prostatectomy specimens: pathological outcomes and risk of biochemical recurrence. Salem S, Chang SS, Clark PE, Davis R, Herrell SD, Kordan Y, Wills ML, Shappell SB, Baumgartner R, Phillips S, Smith JA, Cookson MS, Barocas DA (2010) J Urol 184(4): 1334-40
    › Primary publication · 20723932 (PubMed)
  54. Rationale for targeted therapies and potential role of pazopanib in advanced renal cell carcinoma. Clark PE (2010) Biologics : 187-97
    › Primary publication · 20714356 (PubMed) · PMC2921256 (PubMed Central)
  55. TRAIL and interferon-alpha act synergistically to induce renal cell carcinoma apoptosis. Clark PE, Polosukhina DA, Gyabaah K, Moses HL, Thorburn A, Zent R (2010) J Urol 184(3): 1166-74
    › Primary publication · 20663526 (PubMed) · PMC2963111 (PubMed Central)
  56. Smaller prostate size predicts high grade prostate cancer at final pathology. Newton MR, Phillips S, Chang SS, Clark PE, Cookson MS, Davis R, Fowke JH, Herrell SD, Baumgartner R, Chan R, Mishra V, Blume JD, Smith JA, Barocas DA (2010) J Urol 184(3): 930-7
    › Primary publication · 20643423 (PubMed)
  57. Preoperative hydronephrosis predicts extravesical and node positive disease in patients undergoing cystectomy for bladder cancer. Stimson CJ, Cookson MS, Barocas DA, Clark PE, Humphrey JE, Patel SG, Smith JA, Chang SS (2010) J Urol 183(5): 1732-7
    › Primary publication · 20299043 (PubMed)
  58. Infant communicating hydroceles--do they need immediate repair or might some clinically resolve? Koski ME, Makari JH, Adams MC, Thomas JC, Clark PE, Pope JC, Brock JW (2010) J Pediatr Surg 45(3): 590-3
    › Primary publication · 20223325 (PubMed)
  59. Comparison of transfusion requirements between open and robotic-assisted laparoscopic radical prostatectomy. Kordan Y, Barocas DA, Altamar HO, Clark PE, Chang SS, Davis R, Herrell SD, Baumgartner R, Mishra V, Chan RC, Smith JA, Cookson MS (2010) BJU Int 106(7): 1036-40
    › Primary publication · 20151960 (PubMed)
  60. Bladder cancer. Morgan TM, Clark PE (2010) Curr Opin Oncol 22(3): 242-9
    › Primary publication · 20150808 (PubMed)
  61. Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology. Levine GN, D'Amico AV, Berger P, Clark PE, Eckel RH, Keating NL, Milani RV, Sagalowsky AI, Smith MR, Zakai N, American Heart Association Council on Clinical Cardiology and Council on Epidemiology and Prevention, the American Cancer Society, and the American Urological Association (2010) CA Cancer J Clin 60(3): 194-201
    › Primary publication · 20124400 (PubMed) · PMC3049943 (PubMed Central)
  62. Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology. Levine GN, D'Amico AV, Berger P, Clark PE, Eckel RH, Keating NL, Milani RV, Sagalowsky AI, Smith MR, Zakai N, American Heart Association Council on Clinical Cardiology and Council on Epidemiology and Prevention, the American Cancer Society, and the American Urological Association (2010) Circulation 121(6): 833-40
    › Primary publication · 20124128 (PubMed) · PMC3023973 (PubMed Central)
  63. Robotic assisted laparoscopic prostatectomy versus radical retropubic prostatectomy for clinically localized prostate cancer: comparison of short-term biochemical recurrence-free survival. Barocas DA, Salem S, Kordan Y, Herrell SD, Chang SS, Clark PE, Davis R, Baumgartner R, Phillips S, Cookson MS, Smith JA (2010) J Urol 183(3): 990-6
    › Primary publication · 20083261 (PubMed)
  64. Open renal biopsy: comorbidities and complications in a contemporary series. Stec AA, Stratton KL, Kaufman MR, Chang SS, Milam DF, Herrell SD, Dmochowski RR, Smith JA, Clark PE, Cookson MS (2010) BJU Int 106(1): 102-6
    › Primary publication · 19874299 (PubMed)
  65. Impact of positive apical surgical margins on likelihood of biochemical recurrence after radical prostatectomy. Kordan Y, Salem S, Chang SS, Clark PE, Cookson MS, Davis R, Herrell SD, Baumgartner R, Phillips S, Smith JA, Barocas DA (2009) J Urol 182(6): 2695-701
    › Primary publication · 19836759 (PubMed)
  66. Pathological stage T2 subgroups to predict biochemical recurrence after prostatectomy. Kordan Y, Chang SS, Salem S, Cookson MS, Clark PE, Davis R, Herrell SD, Baumgartner R, Phillips S, Smith JA, Barocas DA (2009) J Urol 182(5): 2291-5
    › Primary publication · 19758638 (PubMed)
  67. Urinary diversion trends at a high volume, single American tertiary care center. Lowrance WT, Rumohr JA, Clark PE, Chang SS, Smith JA, Cookson MS (2009) J Urol 182(5): 2369-74
    › Primary publication · 19758613 (PubMed)
  68. Immediate surgical outcomes for radical prostatectomy in the University HealthSystem Consortium Clinical Data Base: the impact of hospital case volume, hospital size and geographical region on 48,000 patients. Mitchell RE, Lee BT, Cookson MS, Barocas DA, Herrell SD, Clark PE, Smith JA, Chang SS (2009) BJU Int 104(10): 1442-5
    › Primary publication · 19681895 (PubMed)
  69. The role of VHL in clear-cell renal cell carcinoma and its relation to targeted therapy. Clark PE (2009) Kidney Int 76(9): 939-45
    › Primary publication · 19657325 (PubMed) · PMC2963106 (PubMed Central)
  70. Men's knowledge and beliefs about prostate cancer: education, race, and screening status. Winterich JA, Grzywacz JG, Quandt SA, Clark PE, Miller DP, Acuña J, Dignan MB, Arcury TA (2009) Ethn Dis 19(2): 199-203
    › Primary publication · 19537233 (PubMed) · PMC2699598 (PubMed Central)
  71. Neoadjuvant versus adjuvant chemotherapy for muscle-invasive bladder cancer. Clark PE (2009) Expert Rev Anticancer Ther 9(6): 821-30
    › Primary publication · 19496719 (PubMed)
  72. Masculinity and the body: how African American and White men experience cancer screening exams involving the rectum. Winterich JA, Quandt SA, Grzywacz JG, Clark PE, Miller DP, Acuña J, Arcury TA (2009) Am J Mens Health 3(4): 300-9
    › Primary publication · 19477742 (PubMed) · PMC2662681 (PubMed Central)
  73. Cytokine genetic polymorphisms and prostate cancer aggressiveness. Zabaleta J, Su LJ, Lin HY, Sierra RA, Hall MC, Sartor AO, Clark PE, Hu JJ, Ochoa AC (2009) Carcinogenesis 30(8): 1358-62
    › Primary publication · 19474090 (PubMed) · PMC2718072 (PubMed Central)
  74. Outcomes of patients undergoing radical cystoprostatectomy for bladder cancer with prostatic involvement on final pathology. Barocas DA, Patel SG, Chang SS, Clark PE, Smith JA, Cookson MS (2009) BJU Int 104(8): 1091-7
    › Primary publication · 19389006 (PubMed)
  75. Bladder cancer. Bischoff CJ, Clark PE (2009) Curr Opin Oncol 21(3): 272-7
    › Primary publication · 19370808 (PubMed)
  76. Risk factors for urothelial carcinoma of the prostate in patients undergoing radical cystoprostatectomy for bladder cancer. Patel SG, Cookson MS, Barocas DA, Clark PE, Smith JA, Chang SS (2009) BJU Int 104(7): 934-7
    › Primary publication · 19338554 (PubMed)
  77. Radical nephrectomy surgical outcomes in the University HealthSystem Consortium Data Base: Impact of hospital case volume, hospital size, and geographic location on 40,000 patients. Mitchell RE, Lee BT, Cookson MS, Barocas DA, Duke Herrell S, Clark PE, Smith JA, Chang SS (2009) Cancer 115(11): 2447-52
    › Primary publication · 19309750 (PubMed)
  78. Intake of plant foods and associated nutrients in prostate cancer risk. Lewis JE, Soler-Vilá H, Clark PE, Kresty LA, Allen GO, Hu JJ (2009) Nutr Cancer 61(2): 216-24
    › Primary publication · 19235037 (PubMed)
  79. Editorial comment on: Vaccine therapy in patients with renal cell carcinoma. Clark PE (2009) Eur Urol 55(6): 1343-4
    › Primary publication · 19201523 (PubMed)
  80. Bladder cancer. Montie JE, Clark PE, Eisenberger MA, El-Galley R, Greenberg RE, Herr HW, Hudes GR, Kuban DA, Kuzel TM, Lange PH, Lele SM, Michalski J, Patterson A, Pohar KS, Richie JP, Sexton WJ, Shipley WU, Small EJ, Trump DL, Walther PJ, Wilson TG, National Comprehensive Cancer Network (2009) J Natl Compr Canc Netw 7(1): 8-39
    › Primary publication · 19176203 (PubMed)
  81. Comparison of American Joint Committee on Cancer pathologic stage T3a versus T3b urothelial carcinoma: analysis of patient outcomes. Boudreaux KJ, Chang SS, Lowrance WT, Rumohr JA, Barocas DA, Cookson MS, Smith JA, Clark PE (2009) Cancer 115(4): 770-5
    › Primary publication · 19152431 (PubMed)
  82. Comparison of american joint committee on cancer pathological stage T2a versus T2b urothelial carcinoma: analysis of patient outcomes in organ confined bladder cancer. Boudreaux KJ, Clark PE, Lowrance WT, Rumohr JA, Barocas DA, Cookson MS, Smith JA, Chang SS (2009) J Urol 181(2): 540-5; discussion 546
    › Primary publication · 19084855 (PubMed)
  83. Chemokine markers predict biochemical recurrence of prostate cancer following prostatectomy. Blum DL, Koyama T, M'Koma AE, Iturregui JM, Martinez-Ferrer M, Uwamariya C, Smith JA, Clark PE, Bhowmick NA (2008) Clin Cancer Res 14(23): 7790-7
    › Primary publication · 19047106 (PubMed) · PMC3050736 (PubMed Central)
  84. Prognostic factors in T3b renal cell carcinoma. Coons BJ, Stec AA, Stratton KL, Chang SS, Cookson MS, Duke Herrell S, Smith JA, Clark PE (2009) World J Urol 27(1): 75-9
    › Primary publication · 19039590 (PubMed) · PMC2963091 (PubMed Central)
  85. Pretreatment prostate-specific antigen velocity is associated with freedom from biochemical recurrence of prostate cancer after low-dose-rate prostate brachytherapy alone. Rossi PJ, Urbanic J, Clark PE, McCullough DL, Lee WR (2008) Brachytherapy 7(4): 286-9
    › Primary publication · 18928924 (PubMed)
  86. The von Hippel-Lindau gene: turning discovery into therapy. Clark PE, Cookson MS (2008) Cancer 113(7 Suppl): 1768-78
    › Primary publication · 18800388 (PubMed) · PMC2963103 (PubMed Central)
  87. Renal peripheral neuroectodermal tumor presenting at age 78: case report. Koski ME, Tedesco JM, Clark PE (2008) ScientificWorldJournal : 830-4
    › Primary publication · 18758660 (PubMed) · PMC5848644 (PubMed Central)
  88. Waiting time from initial urological consultation to nephrectomy for renal cell carcinoma--does it affect survival? Stec AA, Coons BJ, Chang SS, Cookson MS, Herrell SD, Smith JA, Clark PE (2008) J Urol 179(6): 2152-7
    › Primary publication · 18423724 (PubMed) · PMC2953870 (PubMed Central)
  89. Sigmoid-urachal-cutaneous fistula in an adult male. Coons BJ, Clark PE, Maynes LJ, Terhune KP, Stokes MC, Beech DJ (2009) Urology 73(2): 444.e5-7
    › Primary publication · 18400263 (PubMed)
  90. Effect of a large prostate gland on open and robotically assisted laparoscopic radical prostatectomy. Chan RC, Barocas DA, Chang SS, Herrell SD, Clark PE, Baumgartner R, Smith JA, Cookson MS (2008) BJU Int 101(9): 1140-4
    › Primary publication · 18399829 (PubMed)
  91. Bladder cancer. Barocas DA, Clark PE (2008) Curr Opin Oncol 20(3): 307-14
    › Primary publication · 18391631 (PubMed)
  92. Contemporary open radical cystectomy: analysis of perioperative outcomes. Lowrance WT, Rumohr JA, Chang SS, Clark PE, Smith JA, Cookson MS (2008) J Urol 179(4): 1313-8; discussion 1318
    › Primary publication · 18289578 (PubMed)
  93. Interactions of cytokine gene polymorphisms in prostate cancer risk. Zabaleta J, Lin HY, Sierra RA, Hall MC, Clark PE, Sartor OA, Hu JJ, Ochoa AC (2008) Carcinogenesis 29(3): 573-8
    › Primary publication · 18174250 (PubMed)
  94. Neovesical-urethral anastomotic stricture after orthotopic urinary diversion: presentation and management. Patel SG, Cookson MS, Clark PE, Smith JA, Chang SS (2008) BJU Int 101(2): 219-22
    › Primary publication · 17941923 (PubMed)
  95. A comparison of the incidence and location of positive surgical margins in robotic assisted laparoscopic radical prostatectomy and open retropubic radical prostatectomy. Smith JA, Chan RC, Chang SS, Herrell SD, Clark PE, Baumgartner R, Cookson MS (2007) J Urol 178(6): 2385-9; discussion 2389-90
    › Primary publication · 17936849 (PubMed)
  96. Recent advances in targeted therapy for renal cell carcinoma. Clark PE (2007) Curr Opin Urol 17(5): 331-6
    › Primary publication · 17762626 (PubMed)
  97. Upper tract transitional cell carcinoma: finding a way forward. Clark PE (2007) Cancer 110(8): 1648-9
    › Primary publication · 17722110 (PubMed)
  98. Association of procedure volume with radical cystectomy outcomes in a nationwide database. Barbieri CE, Lee B, Cookson MS, Bingham J, Clark PE, Smith JA, Chang SS (2007) J Urol 178(4 Pt 1): 1418-21; discussion 1421-2
    › Primary publication · 17706712 (PubMed)
  99. Male breast cancer during treatment with leuprolide for prostate cancer. Yacoub J, Richardson C, Farmer M, Lee WR, Clark PE, Hurt G, Levine EA (2007) Clin Adv Hematol Oncol 5(7): 555-6; discussion 556-7
    › Primary publication · 17679929 (PubMed)
  100. Tumor-derived mutations in the TRAIL receptor DR5 inhibit TRAIL signaling through the DR4 receptor by competing for ligand binding. Bin L, Thorburn J, Thomas LR, Clark PE, Humphreys R, Thorburn A (2007) J Biol Chem 282(38): 28189-94
    › Primary publication · 17666396 (PubMed)
  101. Oncologic efficacy of CT-guided percutaneous radiofrequency ablation of renal cell carcinomas. Zagoria RJ, Traver MA, Werle DM, Perini M, Hayasaka S, Clark PE (2007) AJR Am J Roentgenol 189(2): 429-36
    › Primary publication · 17646471 (PubMed)
  102. Assessing retroperitoneal lymphadenectomy experience in United States urological residency programs. Lowrance WT, Cookson MS, Clark PE, Smith JA, Chang SS (2007) J Urol 178(2): 500-3; discussion 503
    › Primary publication · 17561148 (PubMed)
  103. CT-guided biopsy for the diagnosis of renal tumors before treatment with percutaneous ablation. Heilbrun ME, Zagoria RJ, Garvin AJ, Hall MC, Krehbiel K, Southwick A, Clark PE (2007) AJR Am J Roentgenol 188(6): 1500-5
    › Primary publication · 17515368 (PubMed)
  104. Does a delay in initiating definitive therapy affect biochemical recurrence rates in men with clinically localized prostate cancer? Phillips JJ, Hall MC, Lee WR, Clark PE (2007) Urol Oncol 25(3): 196-200
    › Primary publication · 17483015 (PubMed)
  105. Microwave ablation of renal parenchymal tumors before nephrectomy: phase I study. Clark PE, Woodruff RD, Zagoria RJ, Hall MC (2007) AJR Am J Roentgenol 188(5): 1212-4
    › Primary publication · 17449761 (PubMed)
  106. Bladder cancer. Clark PE (2007) Curr Opin Oncol 19(3): 241-7
    › Primary publication · 17414643 (PubMed)
  107. A simple model predicts freedom from biochemical recurrence after low-dose rate prostate brachytherapy alone. Papagikos MA, Rossi PJ, Urbanic JJ, deGuzman AF, McCullough DL, Clark PE, Lee WR (2007) Am J Clin Oncol 30(2): 199-204
    › Primary publication · 17414471 (PubMed)
  108. Vinorelbine, doxorubicin, and prednisone in androgen-independent prostate cancer. Borden LS, Clark PE, Lovato J, Hall MC, Stindt D, Harmon M, M Mohler R, Torti FM (2006) Cancer 107(5): 1093-100
    › Primary publication · 16888761 (PubMed)
  109. Phase I-II prospective dose-escalating trial of lycopene in patients with biochemical relapse of prostate cancer after definitive local therapy. Clark PE, Hall MC, Borden LS, Miller AA, Hu JJ, Lee WR, Stindt D, D'Agostino R, Lovato J, Harmon M, Torti FM (2006) Urology 67(6): 1257-61
    › Primary publication · 16765186 (PubMed)
  110. Complementary and alternative medicine for advanced prostate cancer. Rackley JD, Clark PE, Hall MC (2006) Urol Clin North Am 33(2): 237-46, viii
    › Primary publication · 16631462 (PubMed)
  111. Bladder cancer. Gwynn ES, Clark PE (2006) Curr Opin Oncol 18(3): 277-83
    › Primary publication · 16552241 (PubMed)
  112. Percentage of positive biopsies associated with freedom from biochemical recurrence after low-dose-rate prostate brachytherapy alone for clinically localized prostate cancer. Rossi PJ, Clark PE, Papagikos MA, McCullough DL, Lee WR (2006) Urology 67(2): 349-53
    › Primary publication · 16461084 (PubMed)
  113. DNA damage levels in prostate cancer cases and controls. Lockett KL, Hall MC, Clark PE, Chuang SC, Robinson B, Lin HY, Su LJ, Hu JJ (2006) Carcinogenesis 27(6): 1187-93
    › Primary publication · 16364923 (PubMed)
  114. Dosimetric quantifiers for low-dose-rate prostate brachytherapy: is V(100) superior to D(90)? Papagikos MA, Deguzman AF, Rossi PJ, McCullough DL, Clark PE, Lee WR (2005) Brachytherapy 4(4): 252-8
    › Primary publication · 16344254 (PubMed)
  115. Recent advances in the treatment of bladder cancer. Gwynn ES, Clark PE, Hall MC (2005) Expert Rev Anticancer Ther 5(6): 1023-30
    › Primary publication · 16336093 (PubMed)
  116. Inflammatory myofibroblastic tumor associated with renal cell carcinoma. Gwynn ES, Clark PE (2005) Urology 66(4): 880
    › Primary publication · 16230166 (PubMed)
  117. Prognostic significance of clinicopathologic and deoxyribonucleic acid flow cytometric variables in non-metastatic renal cell carcinoma in the modern era. Clark PE, Veys JA, Eskridge MR, Woodruff RD, Hall MC (2005) Urol Oncol 23(5): 328-32
    › Primary publication · 16144666 (PubMed)
  118. Radical cystectomy in the elderly: comparison of clincal outcomes between younger and older patients. Clark PE, Stein JP, Groshen SG, Cai J, Miranda G, Lieskovsky G, Skinner DG (2005) Cancer 104(1): 36-43
    › Primary publication · 15912515 (PubMed)
  119. Contemporary management of the urethra in patients after radical cystectomy for bladder cancer. Clark PE, Hall MC (2005) Urol Clin North Am 32(2): 199-206
    › Primary publication · 15862617 (PubMed)
  120. Bladder cancer. Borden LS, Clark PE, Hall MC (2005) Curr Opin Oncol 17(3): 275-80
    › Primary publication · 15818174 (PubMed)
  121. A rare case of an extra-adrenal myelolipoma arising in the renal sinus: a case report and review of the literature. Clark PE, Farver CF, Ulchaker JC, Angermeier K (2005) ScientificWorldJournal : 109-17
    › Primary publication · 15702223 (PubMed) · PMC5936534 (PubMed Central)
  122. Radical cystectomy in the elderly: Comparison of survival between younger and older patients. Clark PE, Stein JP, Groshen SG, Cai J, Miranda G, Lieskovsky G, Skinner DG (2005) Cancer 103(3): 546-52
    › Primary publication · 15630702 (PubMed)
  123. The management of urethral transitional cell carcinoma after radical cystectomy for invasive bladder cancer. Clark PE, Stein JP, Groshen SG, Miranda G, Cai J, Lieskovsky G, Skinner DG (2004) J Urol 172(4 Pt 1): 1342-7
    › Primary publication · 15371837 (PubMed)
  124. Endourologic management of upper tract transitional cell carcinoma. Clark PE, Streem SB (2004) ScientificWorldJournal : 62-75
    › Primary publication · 15349530 (PubMed) · PMC5956511 (PubMed Central)
  125. The ADPRT V762A genetic variant contributes to prostate cancer susceptibility and deficient enzyme function. Lockett KL, Hall MC, Xu J, Zheng SL, Berwick M, Chuang SC, Clark PE, Cramer SD, Lohman K, Hu JJ (2004) Cancer Res 64(17): 6344-8
    › Primary publication · 15342424 (PubMed)
  126. Utility of frozen section analysis of resection margins during partial nephrectomy. Kubinski DJ, Clark PE, Assimos DG, Hall MC (2004) Urology 64(1): 31-4
    › Primary publication · 15245928 (PubMed)
  127. Percutaneous CT-guided radiofrequency ablation of renal neoplasms: factors influencing success. Zagoria RJ, Hawkins AD, Clark PE, Hall MC, Matlaga BR, Dyer RB, Chen MY (2004) AJR Am J Roentgenol 183(1): 201-7
    › Primary publication · 15208139 (PubMed)
  128. Phase II trial of combination interferon-alpha and thalidomide as first-line therapy in metastatic renal cell carcinoma. Clark PE, Hall MC, Miller A, Ridenhour KP, Stindt D, Lovato JF, Patton SE, Brinkley W, Das S, Torti FM (2004) Urology 63(6): 1061-5
    › Primary publication · 15183950 (PubMed)
  129. Bladder cancer. Borden LS, Clark PE, Hall MC (2004) Curr Opin Oncol 16(3): 257-62
    › Primary publication · 15069323 (PubMed)
  130. Radiofrequency ablation of renal tumors. Matlaga BR, Zagoria RJ, Clark PE, Hall MC (2004) Curr Urol Rep 5(1): 39-44
    › Primary publication · 14733836 (PubMed)
  131. Microscopic and gross extravesical extension in pathological staging of bladder cancer. Quek ML, Stein JP, Clark PE, Daneshmand S, Miranda G, Cai J, Groshen S, Cote RJ, Lieskovsky G, Quinn DI, Skinner DG (2004) J Urol 171(2 Pt 1): 640-5
    › Primary publication · 14713777 (PubMed)
  132. Prostate cancer and bone metastases: medical treatment. Clark PE, Torti FM (2003) Clin Orthop Relat Res (415 Suppl): S148-57
    › Primary publication · 14600605 (PubMed)
  133. Natural history of surgically treated bladder carcinoma with extravesical tumor extension. Quek ML, Stein JP, Clark PE, Daneshmand S, Miranda G, Cai J, Groshen S, Lieskovsky G, Quinn DI, Raghavan D, Skinner DG (2003) Cancer 98(5): 955-61
    › Primary publication · 12942562 (PubMed)
  134. Bladder cancer. Borden LS, Clark PE, Hall MC (2003) Curr Opin Oncol 15(3): 227-33
    › Primary publication · 12778017 (PubMed)
  135. The androgen receptor CAG repeat and prostate cancer risk. Clark PE, Irvine RA, Coetzee GA (2003) Methods Mol Med : 255-66
    › Primary publication · 12725125 (PubMed)
  136. Androgen receptor activity at the prostate specific antigen locus: steroidal and non-steroidal mechanisms. Jia L, Kim J, Shen H, Clark PE, Tilley WD, Coetzee GA (2003) Mol Cancer Res 1(5): 385-92
    › Primary publication · 12651911 (PubMed)
  137. Angiomyolipoma with vena caval extension. Wilson SS, Clark PE, Stein JP (2002) Urology 60(4): 695-6
    › Primary publication · 12385937 (PubMed)
  138. Urinary diversion after radical cystectomy. Clark PE (2002) Curr Treat Options Oncol 3(5): 389-402
    › Primary publication · 12194804 (PubMed)
  139. Phase II trial of neoadjuvant estramustine and etoposide plus radical prostatectomy for locally advanced prostate cancer. Clark PE, Peereboom DM, Dreicer R, Levin HS, Clark SB, Klein EA (2001) Urology 57(2): 281-5
    › Primary publication · 11182337 (PubMed)
  140. Quality of life and psychological adaptation after surgical treatment for localized renal cell carcinoma: impact of the amount of remaining renal tissue. Clark PE, Schover LR, Uzzo RG, Hafez KS, Rybicki LA, Novick AC (2001) Urology 57(2): 252-6
    › Primary publication · 11182331 (PubMed)
  141. Exophytic noninvasive growth pattern of renal angiomyolipomas: implications for nephron sparing surgery. Clark PE, Novick AC (2001) J Urol 165(2): 513-4
    › Primary publication · 11176411 (PubMed)
  142. Surgery for invasive bladder tumors: technique and outcome. Clark PE, Klein EA (1999) Curr Opin Urol 9(5): 413-8
    › Primary publication · 10579079 (PubMed)
  143. Renal cell carcinoma-derived gangliosides suppress nuclear factor-kappaB activation in T cells. Uzzo RG, Rayman P, Kolenko V, Clark PE, Cathcart MK, Bloom T, Novick AC, Bukowski RM, Hamilton T, Finke JH (1999) J Clin Invest 104(6): 769-76
    › Primary publication · 10491412 (PubMed) · PMC408430 (PubMed Central)
  144. Mechanisms of apoptosis in T cells from patients with renal cell carcinoma. Uzzo RG, Rayman P, Kolenko V, Clark PE, Bloom T, Ward AM, Molto L, Tannenbaum C, Worford LJ, Bukowski R, Tubbs R, Hsi ED, Bander NH, Novick AC, Finke JH (1999) Clin Cancer Res 5(5): 1219-29
    › Primary publication · 10353760 (PubMed)
  145. Alterations in NFkappaB activation in T lymphocytes of patients with renal cell carcinoma. Uzzo RG, Clark PE, Rayman P, Bloom T, Rybicki L, Novick AC, Bukowski RM, Finke JH (1999) J Natl Cancer Inst 91(8): 718-21
    › Primary publication · 10218511 (PubMed)
  146. 13-year experience with percutaneous management of upper tract transitional cell carcinoma. Clark PE, Streem SB, Geisinger MA (1999) J Urol 161(3): 772-5; discussion 775-6
    › Primary publication · 10022682 (PubMed)
  147. A review of scrotal violation in testicular cancer: is adjuvant local therapy necessary? Capelouto CC, Clark PE, Ransil BJ, Loughlin KR (1995) J Urol 153(3 Pt 2): 981-5
    › Primary publication · 7853587 (PubMed)